The recent start of construction of its new 60,000 square foot manufacturing facility at Kent Science Park (KSP), Sittingbourne in the UK, represents an investment of over $100m (approximately £75m) by Jazz Pharmaceuticals plc and its subsidiary, GW Pharmaceuticals. Planned to create more than 100 new, highly skilled jobs when operational, the facility was designed to support the company’s two regulatory-approved cannabis medicines and future capacity for new medicines under development. Currently manufacturing the extract, active pharmaceutical ingredients and formulated pharmaceuticals at KSP, occupying 12 buildings with over 400 employees, the company said the UK has become the heart of its global cannabinoid manufacturing operations.
The design of the facility also takes the environment into account; animal shelter boxes will be installed to promote wildlife in the area, the use of single-use plastics will be kept to a minimum, and more than 1,100 solar panels will be installed to provide some of the building’s energy consumption.
“The UK has been our home for over two decades. This strategic investment underscores Jazz’s continued commitment to the UK and will help us bring potentially game-changing medicines to more patients in desperate need in the UK and around the world,” said Chris Tovey, Vice-President Executive Chairman, Chief Operating Officer and Chief Executive Officer. , Europe & International at Jazz Pharmaceuticals. “We are delighted to have started construction of this state-of-the-art facility in Kent, which will create over 100 highly skilled permanent jobs. This facility, which is expected to open in 2024, will not only significantly increase our ability to meet the growing demand for our medicines, but will also help us maintain our position as a world leader in cannabinoid science.
More information in line